VirologyNews.net

Virology Xagena

The results from a multi-arm phase 2 clinical trial evaluating Grazoprevir / Elbasvir ( MK-5172 / MK-8742, the investigational NS3/4A protease inhibitor and NS5A inhibitor, respectively ) with or wit ...


Data from the ALLY trial investigating a Ribavirin-free 12-week regimen of Daclatasvir ( DCV ) in combination with Sofosbuvir ( SOF ) in genotype 3 hepatitis C ( HCV ) patients, a patient population t ...


Results from studies in chronic hepatitis C patients with human immunodeficiency virus type 1 ( HIV-1 ) co-infection ( TURQUOISE-I ) and liver transplant recipients ( CORAL-I ) were presented at The L ...


A commonly-used HIV drug has been shown to kill off the human papillomavirus ( HPV ) that leads to cervical cancer in a world-first clinical trial. Researchers have examined Kenyan women diagnosed w ...


Researchers have successfully treated the deadly Ebola virus in infected animals following onset of disease symptoms, according to a report published in Science Translational Medicine. The results s ...


Short-course antiretroviral therapy ( ART ) in primary human immunodeficiency virus ( HIV ) infection may delay disease progression but has not been adequately evaluated.Researchers randomly assigned ...


Interim data presented recently have shown that all patients ( 13/13 ) who reached their 4-weeks post-treatment follow-up have undetectable levels of hepatitis C virus ( SVR4 ) after completing a 12-w ...


Planning for outbreaks of influenza is a high priority public health issue for national governments. Neuraminidase inhibitors are thought to help reduce the symptoms of influenza with several possible ...


A study has found Telaprevir ( VX-950; Incivek, Incivo ), a protease inhibitor, combined with standard hepatitis C treatment, cures a significantly higher number of difficult-to-treat patients th ...


A study to assess the adverse effects of anti-retroviral drugs has shown that two widely-used HIV drugs are associated with an increased risk of myocardial infarction and formation of blood clots in t ...


Even with effective anti-HIV therapies, physicians still have not been able to eradicate the virus from infected individuals who are receiving such treatments, largely because of the persistence of HI ...


Studies 102 and 103 have compared Viread ( Tenofovir disoproxil ) to Hepsera ( Adefovir dipivoxil ) among patients with HBeAg-negative chronic hepatitis B and patients with HBeAg-positive hepatitis B, ...


Treatment with an investigational drug that induces the release of growth hormone significantly improved the symptoms of HIV lipodystrophy, a condition involving the redistribution of fat and other me ...


A preliminary study suggests there may be hope in the offing for some sufferers of chronic fatigue syndrome ( CSF ) with a new therapy being tested by researchers at the Stanford University School of ...


Stopping antiretroviral therapy in HIV-infected patients from time to time could reduce the side effects and costs of the treatment. Though extremely effective at preventing AIDS, lifelong treatmen ...


Researchers at the University of Illinois at Chicago and two other institutions have unraveled the structure of an important new drug target from the virus that causes SARS, severe acute respiratory s ...


A study has examined the function of a protein called HBZ, which is made by the human T cell leukemia virus type 1 ( HTLV-1 ), a retrovirus. The findings showed that HBZ enhances the ability of HTLV- ...


Researchers from the University of Massachusetts and the University of Pennsylvania have shown that race/ethnicity is a predictor of plasma lipids in patients with HIV-1 on HAART ( Highly Active AntiR ...


The human body has a unique immune system response to foreign DNA, suggesting that DNA viruses and RNA viruses are detected by different mechanisms. Yale School of Medicine researchers also found t ...


The data from a phase I/II study showed significant reductions in viral load among HIV-positive patients receiving GS 9137, or JTK-303, a novel oral HIV integrase inhibitor, as monotherapy or in comb ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati